Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
March 14, 2024 17:23 ET
|
Aquestive Therapeutics, Inc.
Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are...
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 05, 2024 17:05 ET
|
Aquestive Therapeutics, Inc.
Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual...
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
February 21, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
February 15, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular...
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
January 30, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through...
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
December 05, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
Commences initial Phase 3 study with first orally delivered epinephrine prodrug candidateReaffirms topline data anticipated in first quarter 2024 WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) --...
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
November 10, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023 16:37 ET
|
Aquestive Therapeutics, Inc.
Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024Completes...
Aquestive Therapeutics Completes $45 Million Debt Refinancing
November 02, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through...
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
October 31, 2023 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful...